keyword
MENU ▼
Read by QxMD icon Read
search

Cell therapy myocardial infarction

keyword
https://www.readbyqxmd.com/read/27913896/mesenchymal-stem-cells-with-enos-over-expression-enhance-cardiac-repair-in-rats-with-myocardial-infarction
#1
Leilei Chen, Yuan Zhang, Liangliang Tao, Zhijian Yang, Liansheng Wang
PURPOSE: Transplantation of mesenchymal stem cells (MSCs) is a promising therapeutic option for patients with acute myocardial infarction. METHODS: We show here that the ectopic overexpression of endothelial nitric oxide synthases (eNOS), an endothelial form of NOS, could enhance the ability of MSCs in treating ischemic heart damage after the occlusion of the coronary artery. RESULTS: Adenoviral delivery of human eNOS gene into mouse bone marrow-derived MSCs (BM-MSCs) conferred resistance to oxygen glucose deprivation (OGD)-induced cell death in vitro, and elevated the bioavailability of nitric oxide when injected into the myocardium in vivo...
December 3, 2016: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/27911047/modified-mrna-as-a-therapeutic-tool-to-induce-cardiac-regeneration-in-ischemic-heart-disease
#2
REVIEW
Yoav Hadas, Michael G Katz, Charles R Bridges, Lior Zangi
Ischemic heart disease (IHD) is a leading cause of morbidity and mortality in developed countries. Current pharmacological and interventional therapies provide significant improvement in the life quality of patient; however, they are mostly symptom-oriented and not curative. A high disease and economic burden of IHD requires the search for new therapeutic strategies to significantly improve patients' prognosis and quality of life. One of the main challenges during IHD is the massive loss of cardiomyocytes that possess minimal regenerative capacity...
December 2, 2016: Wiley Interdisciplinary Reviews. Systems Biology and Medicine
https://www.readbyqxmd.com/read/27903535/magnetic-resonance-imaging-of-cardiac-strain-pattern-following-transplantation-of-human-tissue-engineered-heart-muscles
#3
Xulei Qin, Johannes Riegler, Malte Tiburcy, Xin Zhao, Tony Chour, Babacar Ndoye, Michael Nguyen, Jackson Adams, Mohamed Ameen, Thomas S Denney, Phillip C Yang, Patricia Nguyen, Wolfram H Zimmermann, Joseph C Wu
BACKGROUND: The use of tissue engineering approaches in combination with exogenously produced cardiomyocytes offers the potential to restore contractile function after myocardial injury. However, current techniques assessing changes in global cardiac performance after such treatments are plagued by relatively low detection ability. Since the treatment is locally performed, this detection could be improved by myocardial strain imaging that measures regional contractility. METHODS AND RESULTS: Tissue engineered heart muscles (EHMs) were generated by casting human embryonic stem cell-derived cardiomyocytes with collagen in preformed molds...
November 2016: Circulation. Cardiovascular Imaging
https://www.readbyqxmd.com/read/27903111/electric-stimulation-enhances-cardiac-differentiation-of-human-induced-pluripotent-stem-cells-for-myocardial-infarction-therapy
#4
Ruilian Ma, Jialiang Liang, Wei Huang, Linlin Guo, WenFeng Cai, Lei Wang, Christian Paul, Huang-Tian Yang, Ha Won Kim, Yigang Wang
AIM: Electrical stimulation (EleS) can promote cardiac differentiation, but the underlying mechanism is not well known. This study investigated the effect of EleS on cardiomyocyte (CM) differentiation of human induced pluripotent stem cells (hiPSCs) and evaluated the therapeutic effects for the treatment of myocardial infarction (MI). RESULTS: Cardiac differentiation of hiPSCs was induced with EleS after embryoid body formation. Spontaneously beating hiPSCs were observed as early at 2 days when treated with EleS as compared to control treatment...
November 30, 2016: Antioxidants & Redox Signaling
https://www.readbyqxmd.com/read/27882430/identification-of-cardiovascular-risk-factors-associated-with-bone-marrow-cell-subsets-in-patients-with-stemi-a-biorepository-evaluation-from-the-cctrn-time-and-latetime-clinical-trials
#5
Ariadna Contreras, Aaron F Orozco, Micheline Resende, Robert C Schutt, Jay H Traverse, Timothy D Henry, Dejian Lai, John P Cooke, Roberto Bolli, Michelle L Cohen, Lem Moyé, Carl J Pepine, Phillip C Yang, Emerson C Perin, James T Willerson, Doris A Taylor
Autologous bone marrow mononuclear cell (BM-MNC) therapy for patients with ST-segment elevation myocardial infarction (STEMI) has produced inconsistent results, possibly due to BM-MNC product heterogeneity. Patient-specific cardiovascular risk factors (CRFs) may contribute to variations in BM-MNC composition. We sought to identify associations between BM-MNC subset frequencies and specific CRFs in STEMI patients. Bone marrow was collected from 191 STEMI patients enrolled in the CCTRN TIME and LateTIME trials...
January 2017: Basic Research in Cardiology
https://www.readbyqxmd.com/read/27878916/can-the-outcomes-of-mesenchymal-stem-cell-based-therapy-for-myocardial-infarction-be-improved-providing-weapons-and-armour-to-cells
#6
REVIEW
Andrey A Karpov, Daria V Udalova, Michael G Pliss, Michael M Galagudza
Use of mesenchymal stem cell (MSC) transplantation after myocardial infarction (MI) has been found to have infarct-limiting effects in numerous experimental and clinical studies. However, recent meta-analyses of randomized clinical trials on MSC-based MI therapy have highlighted the need for improving its efficacy. There are two principal approaches for increasing therapeutic effect of MSCs: (i) preventing massive MSC death in ischaemic tissue and (ii) increasing production of cardioreparative growth factors and cytokines with transplanted MSCs...
November 23, 2016: Cell Proliferation
https://www.readbyqxmd.com/read/27872050/experimental-systems-and-computational-approaches-to-understanding-the-microrna-mediated-reparative-potential-of-cardiac-progenitor-cell-derived-exosomes-from-pediatric-patients
#7
Udit Agarwal, Alex George, Srishti Bhutani, Shohini Ghosh-Choudhary, Josh T Maxwell, Milton E Brown, Yash Mehta, Manu O Platt, Yaxuan Liang, Susmita Sahoo, Michael E Davis
RATIONALE: Studies have demonstrated that exosomes can repair cardiac tissue post myocardial infarction (MI) and recapitulate the benefits of cellular therapy. OBJECTIVE: We evaluated the role of donor age and hypoxia of human pediatric cardiac progenitor cell (CPC)-derived exosomes, in a rat model of ischemia reperfusion (IR) injury. METHODS AND RESULTS: Human CPCs from the right atrial appendages from children of different ages undergoing cardiac surgery for congenital heart defects were isolated and cultured under hypoxic or normoxic conditions...
November 21, 2016: Circulation Research
https://www.readbyqxmd.com/read/27866022/novel-approaches-toward-the-generation-of-bioscaffolds-as-a-potential-therapy-in-cardiovascular-tissue-engineering
#8
REVIEW
Fahimeh Shahabipour, Maciej Banach, Thomas P Johnston, Matteo Pirro, Amirhossein Sahebkar
Cardiovascular disease associated with myocardial infarction (MI) is among the leading causes of mortality worldwide, in part, due to the limited regenerative capacity of tissues. Although various approaches have been employed to generate bioartificial myocardial tissues, including surgical reconstruction and the use of biosynthetic or biological cell-free grafts, many challenges still remain. Natural biomaterials based on decellularization have made significant inroads into the development of favorable biomatrices for myocardial tissue regeneration...
November 9, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27864105/epigallocatechin-3-gallate-prevents-cardiac-apoptosis-by-modulating-the-intrinsic-apoptotic-pathway-in-isoproterenol-induced-myocardial-infarction
#9
Azza I Othman, Magda M Elkomy, M A El-Missiry, Mohammed Dardor
(-)Epigallocatechin-gallate (EGCG) is an emerging natural therapy. This study examined the cardioprotective effect of EGCG on isoproterenol-induced myocardial damage and apoptosis and EGCG's role in modulating the expression of apoptotic signaling proteins. Experimental myocardial infarction was induced in albino Westar rats by isoproterenol (ISO) administration (100mg/kg, s.c.) at an interval of 24h on the 6th and 7th day. EGCG (15mg/kg, i.p.) was administered seven days before ISO. EGCG pretreatment significantly showed an anti-lipidemic effect and protected the cell membrane integrity, as shown by the blocking of changes in serum levels of CK-MB, LDH, ALP, ALT and troponin T...
November 15, 2016: European Journal of Pharmacology
https://www.readbyqxmd.com/read/27837566/cryopreservation-and-banking-of-dental-stem-cells
#10
Petra Hilkens, Ronald B Driesen, Esther Wolfs, Pascal Gervois, Tim Vangansewinkel, Jessica Ratajczak, Yörg Dillen, Annelies Bronckaers, Ivo Lambrichts
Over the past decade, dental tissues have become an attractive source of mesenchymal stem cells (MSCs). Dental stem cells (DSCs) are not only able to differentiate into adipogenic, chondrogenic and osteogenic lineanges, but an increasing amount of research also pointed out their potential applicability in numerous clinical disorders, such as myocardial infarction, neurodegenerative diseases and diabetes. Together with their multilineage differentiation capacity, their easy availability from extracted third molars makes these stem cells a suitable alternative for bone marrow-derived MSCs...
2016: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/27834476/bone-marrow-cells-for-heart-repair-clinical-evidence-and-perspectives
#11
Anweshan Samanta, Ajay K Kaja, Muhammad R Afzal, Ewa K Zuba-Surma, Buddhadeb Dawn
More than 15 years ago, bone marrow cell (BMC) therapy for cardiac repair was hailed as a highly promising and revolutionary treatment approach that was poised to benefit countless patients with ischemic heart disease (IHD) and heart failure. The ensuing years have unfortunately witnessed endless controversy not only about the mechanisms of action of cardiac repair with cell therapy, but also regarding the efficacy of such approach. Somewhat discordant results from smaller clinical trials with diverse study designs, BMC types, routes of injection, timing after myocardial infarction (MI), and other key study variables have been less than conclusive...
November 11, 2016: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/27821724/preserve-ami-a-randomized-double-blind-placebo-controlled-clinical-trial-of-intracoronary-administration-of-autologous-cd34-cells-in-patients-with-left-ventricular-dysfunction-post-stemi
#12
Arshed A Quyyumi, Alejandro Vasquez, Dean Kereiakes, Marc Klapholz, Gary L Schaer, Ahmed Abdel-Latif, Stephen Frohwein, Timothy D Henry, Richard A Schatz, Nabil Dib, Catalin Toma, Charles J Davidson, Gregory W Barsness, David Shavelle, Martin Cohen, Joseph Poole, Thomas J Moss, Pamela Hyde, AnnaMaria Kanakaraj, Vitaly Druker, Amy Chung, Candice Junge, Robert A Preti, Robin L Smith, David J Mazzo, Andrew Pecora, Douglas W Losordo
RATIONALE: Despite direct immediate intervention and therapy, ST segment Elevation Myocardial Infarction (STEMI) victims remain at risk for infarct expansion, heart failure, re-infarction, repeat revascularization and death. OBJECTIVE: To evaluate the safety and bioactivity of autologous CD34+ cell (CLBS10) intracoronary infusion in patients with left ventricular dysfunction (LVD) post-STEMI. METHODS AND RESULTS: Patients who underwent successful stenting for STEMI and had LVD (ejection fraction [EF] ≤48%) ≥4 days post-stent were eligible for enrollment...
November 7, 2016: Circulation Research
https://www.readbyqxmd.com/read/27804974/mesenchymal-stem-cells-combined-with-hepatocyte-growth-factor-therapy-for-attenuating-ischaemic-myocardial-fibrosis-assessment-using-multimodal-molecular-imaging
#13
Huizhu Chen, Rui Xia, Zhenlin Li, Lizhi Zhang, Chunchao Xia, Hua Ai, Zhigang Yang, Yingkun Guo
Clinically, myocardial fibrosis is increasingly being recognized as a new therapeutic target for ischaemic heart diseases. The aim of this study was to investigate whether noninvasive multimodal molecular imaging could be used to dynamically assess whether the combination of bone marrow mesenchymal stem cells (BMSCs) and hepatocyte growth factor (HGF) therapy can synergistically attenuate myocardial fibrosis after myocardial infarction (MI). MI was induced in 28 rats by coronary ligation with subsequent injection of BMSCs/HGF, BMSCs, HGF, or saline into the border zone under echocardiography guidance...
November 2, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27791385/novel-cardioprotective-and-regenerative-therapies-in-acute-myocardial-infarction-a-review-of-recent-and-ongoing-clinical-trials
#14
Nicholas B Spath, Nicholas L Mills, Nicholas L Cruden
Following the original large-scale randomized trials of aspirin and β-blockade, there have been a number of major advances in pharmacological and mechanical treatments for acute myocardial infarction. Despite this progress, myocardial infarction remains a major global cause of mortality and morbidity, driving a quest for novel treatments in this area. As the understanding of mitochondrial dynamics and the pathophysiology of reperfusion injury has evolved, the last three decades have seen advances in ischemic conditioning, pharmacological and metabolic cardioprotection, as well as biological and stem-cell therapies...
October 28, 2016: Future Cardiology
https://www.readbyqxmd.com/read/27790620/immune-modulation-of-cardiac-repair-and-regeneration-the-art-of-mending-broken-hearts
#15
REVIEW
Ivana Zlatanova, Cristina Pinto, Jean-Sébastien Silvestre
The accumulation of immune cells is among the earliest responses that manifest in the cardiac tissue after injury. Both innate and adaptive immunity coordinate distinct and mutually non-exclusive events governing cardiac repair, including elimination of the cellular debris, compensatory growth of the remaining cardiac tissue, activation of resident or circulating precursor cells, quantitative and qualitative modifications of the vascular network, and formation of a fibrotic scar. The present review summarizes the mounting evidence suggesting that the inflammatory response also guides the regenerative process following cardiac damage...
2016: Frontiers in Cardiovascular Medicine
https://www.readbyqxmd.com/read/27786170/bioengineering-of-injectable-encapsulated-aggregates-of-pluripotent-stem-cells-for-therapy-of-myocardial-infarction
#16
Shuting Zhao, Zhaobin Xu, Hai Wang, Benjamin E Reese, Liubov V Gushchina, Meng Jiang, Pranay Agarwal, Jiangsheng Xu, Mingjun Zhang, Rulong Shen, Zhenguo Liu, Noah Weisleder, Xiaoming He
It is difficult to achieve minimally invasive injectable cell delivery while maintaining high cell retention and animal survival for in vivo stem cell therapy of myocardial infarction. Here we show that pluripotent stem cell aggregates pre-differentiated into the early cardiac lineage and encapsulated in a biocompatible and biodegradable micromatrix, are suitable for injectable delivery. This method significantly improves the survival of the injected cells by more than six-fold compared with the conventional practice of injecting single cells, and effectively prevents teratoma formation...
October 27, 2016: Nature Communications
https://www.readbyqxmd.com/read/27775615/microrna-mediated-down-regulation-of-apoptosis-signal-regulating-kinase-1-ask1-attenuates-the-apoptosis-of-human-mesenchymal-stem-cells-mscs-transplanted-into-infarcted-heart
#17
Chang Youn Lee, Sunhye Shin, Jiyun Lee, Hyang-Hee Seo, Kyu Hee Lim, Hyemin Kim, Jung-Won Choi, Sang Woo Kim, Seahyung Lee, Soyeon Lim, Ki-Chul Hwang
Stem cell therapy using adult stem cells, such as mesenchymal stem cells (MSCs) has produced some promising results in treating the damaged heart. However, the low survival rate of MSCs after transplantation is still one of the crucial factors that limit the therapeutic effect of stem cells. In the damaged heart, oxidative stress due to reactive oxygen species (ROS) production can cause the death of transplanted MSCs. Apoptosis signal-regulating kinase 1 (ASK1) has been implicated in the development of oxidative stress-related pathologic conditions...
October 20, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27774971/acute-myocardial-infarction-in-a-patient-with-sickle-cell-trait
#18
Oğuz Akkuş, Mustafa Topuz, Ali Deniz
Presently described is the rare complication of sickle cell trait (HbAS) with acute inferior myocardial infarction in a young adult patient. Angiogram revealed microemboli in the distal thin segment of the circumflex (Cx) artery. Anticoagulant and anti-aggregant therapies were initiated to restore Cx artery flow. HbAS was detected as an underlying pathology. ST segments returned to the isoelectric line and the patient became asymptomatic.
October 2016: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/27765070/discrepancy-between-short-term-and-long-term-effects-of-bone-marrow-derived-cell-therapy-in-acute-myocardial-infarction-a-systematic-review-and-meta-analysis
#19
Seon Heui Lee, Jin Hyuk Hong, Kyoung Hee Cho, Jin-Won Noh, Hyun-Jai Cho
BACKGROUND: Bone marrow-derived cell therapy has been used to treat acute myocardial infarction. However, the therapeutic efficacy of this approach remains controversial. Here, we performed a systematic review and meta-analysis to evaluate short-term and long-term effectiveness of bone marrow-derived therapy. METHODS: We searched eight databases (Ovid-Medline, Ovid-EMBASE, Cochrane Library, KoreaMed, KMBASE, KISS, RISS, and KisTi) up to December 2014. Demographic characteristics, clinical outcomes, and adverse events were analyzed...
October 20, 2016: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/27764157/long-term-outcome-of-combined-percutaneous-intramyocardial-and-intracoronary-application-of-autologous-bone-marrow-mononuclear-cells-post-myocardial-infarction-the-5-year-mystar-study
#20
Mariann Gyöngyösi, Georgiana-Aura Giurgea, Bonni Syeda, Silvia Charwat, Beatrice Marzluf, Julia Mascherbauer, Andras Jakab, Abelina Zimba, Márta Sárközy, Noemi Pavo, Heinz Sochor, Senta Graf, Irene Lang, Gerald Maurer, Jutta Bergler-Klein
OBJECTIVE: The long-term (5-year) outcome of early (3-6 weeks after acute myocardial infarction [AMI], BM-MNC Early group) and late (3-4 months after AMI, BM-MNC Late group) combined (percutaneous intramyocardial and intracoronary) delivery of autologous bone marrow mononuclear cells (BM-MNCs) was evaluated in patients with ejection fractions (EF) between 30-45% post-AMI. METHODS: Major adverse cardiac and cerebrovascular events (MACCE) and hospitalization were recorded...
2016: PloS One
keyword
keyword
58905
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"